Last reviewed · How we verify

Allogenic Human Islet Cells

City of Hope Medical Center · Phase 2 active Biologic

Allogenic Human Islet Cells is a Cell therapy Biologic drug developed by City of Hope Medical Center. It is currently in Phase 2 development for Type 1 diabetes mellitus with severe hypoglycemic unawareness, Brittle diabetes with recurrent severe hypoglycemic episodes. Also known as: Islet transplant, islet transplantation.

Allogeneic human islet cells restore insulin-producing capacity by replacing or supplementing the patient's own dysfunctional beta cells.

Allogeneic human islet cells restore insulin-producing capacity by replacing or supplementing the patient's own dysfunctional beta cells. Used for Type 1 diabetes mellitus with severe hypoglycemic unawareness, Brittle diabetes with recurrent severe hypoglycemic episodes.

At a glance

Generic nameAllogenic Human Islet Cells
Also known asIslet transplant, islet transplantation
SponsorCity of Hope Medical Center
Drug classCell therapy
ModalityBiologic
Therapeutic areaDiabetes
PhasePhase 2

Mechanism of action

This cell therapy involves transplanting insulin-secreting islet cells derived from donor pancreatic tissue into patients with type 1 diabetes or other conditions of severe insulin deficiency. The transplanted cells engraft and function to produce and release insulin in response to blood glucose levels, thereby restoring endogenous glucose regulation. The allogeneic (non-self) source requires immunosuppression to prevent rejection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Allogenic Human Islet Cells

What is Allogenic Human Islet Cells?

Allogenic Human Islet Cells is a Cell therapy drug developed by City of Hope Medical Center, indicated for Type 1 diabetes mellitus with severe hypoglycemic unawareness, Brittle diabetes with recurrent severe hypoglycemic episodes.

How does Allogenic Human Islet Cells work?

Allogeneic human islet cells restore insulin-producing capacity by replacing or supplementing the patient's own dysfunctional beta cells.

What is Allogenic Human Islet Cells used for?

Allogenic Human Islet Cells is indicated for Type 1 diabetes mellitus with severe hypoglycemic unawareness, Brittle diabetes with recurrent severe hypoglycemic episodes.

Who makes Allogenic Human Islet Cells?

Allogenic Human Islet Cells is developed by City of Hope Medical Center (see full City of Hope Medical Center pipeline at /company/city-of-hope-medical-center).

Is Allogenic Human Islet Cells also known as anything else?

Allogenic Human Islet Cells is also known as Islet transplant, islet transplantation.

What drug class is Allogenic Human Islet Cells in?

Allogenic Human Islet Cells belongs to the Cell therapy class. See all Cell therapy drugs at /class/cell-therapy.

What development phase is Allogenic Human Islet Cells in?

Allogenic Human Islet Cells is in Phase 2.

What are the side effects of Allogenic Human Islet Cells?

Common side effects of Allogenic Human Islet Cells include Graft rejection, Immunosuppression-related infections, Immunosuppression-related malignancy risk, Bleeding or thrombosis at transplant site.

Related